Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by robertshawon Jul 25, 2019 1:35pm
60 Views
Post# 29960075

RE:RE:RE:RE:RE:UP

RE:RE:RE:RE:RE:UP
Watchmen wrote: A rights issue assumes that the concept of protecting current shareholders was a factor in the equation. Anyone believe that? Not me.  I'm more likely to believe that the attitude was "F them, if they want to sell into a rapidly declining valuation than they have that opportunity". In the end current shareholders will have contributed to the raise, albeit at  diluted rate. I have no problem with those that had the stones to do so, and they deserve their warrant in the process. I can't wait to see if and what the insider haul was here on this sell off financing. One hand in the cookie jar and sitting on the other during the downswing could get an OSC eyebrow raised.


Yes, to protect the long shareholders' value is the common sense and the most important thing the pimp (prostitute) management should have learned 5 years ago, but the idiot management (prostitute party members ) are so addicted to dirty cheap PP and never care about long shareholders' value. The only hope is the science side now, but the long shareholders should bear in mind the idiot style management really doesn't match this brilliant technology, how to curb them from screwing all the long suffered shareholders again even when the great data comes from Phase 2 is most important.
Bullboard Posts